Background Barriers to cancer clinical trial participation have been the subject of frequent
study, but the rate of trial participation has not changed substantially over time. Studies often …

Objective To present a summary of the 2013 version of the European Association of Urology
(EAU) guidelines on the treatment of advanced, relapsing, and castration-resistant prostate …

Background Injectable luteinizing hormone–releasing hormone agonists (eg, leuprolide) are
the standard agents for achieving androgen deprivation for prostate cancer despite the initial …

Purpose Evolving treatments, disease phenotypes, and biology, together with a changing
drug development environment, have created the need to revise castration-resistant prostate …

Purpose: Decisions to continue or suspend therapy with immune checkpoint inhibitors are
commonly guided by tumor dynamics seen on serial imaging. However, immunotherapy …

The aim of this evaluation was to identify the first indicators of efficacy for 225Ac-labeled
prostate-specific membrane antigen (PSMA)–617 therapy in a retrospectively analyzed …

Background The role of chemotherapy in metastatic non castrate prostate cancer (mNCPC)
is debated. Survival benefits of docetaxel (D) added to androgen-deprivation therapy (ADT) …

Background Abiraterone acetate improved overall survival in metastatic castration-resistant
prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo …

Background Biosynthesis of extragonadal androgen may contribute to the progression of
castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor …

Background Early chemotherapy might improve the overall outcomes of patients with
metastatic non-castrate (ie, hormone-sensitive) prostate cancer. We investigated the effects …